-
CD80: Amplifying Immune Activation Through Co-Stimulatory Pathways(Post)
Introduction to CD80 and Its Role in Immune Activation CD80 is a critical immune checkpoint molecule that plays an essential role in T cell activation through co-stimulatory pathways. Exp
Beyond Burnout: How T Cell Exhaustion Hijacks Cancer Immunity and What We Can Do About It(Post)Imagine a highly trained soldier, elite and effective, sent to the front lines of a relentless war. Day after day, they fight without rest, their supplies dwindle, and the enemy never stops coming. Ev
The double-edged sword in prostate cancer therapy(Post)By Zoe Angel, PhD Student, Ulster University Prostate cancer is now the commonest cancer in men and it is the fifth leading cause of death (1). Researchers h
Car t signalling pathway · H(Page) Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying
Novel Gene Therapy for Cystic Fibrosis (Post)Novel Gene Therapies for Cystic Fibrosis Cystic Fibrosis Cystic fibrosis (CF) is an autosomal recessive, life-limiting disease resulting from gene mutations that encode the cystic fibr
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Dupilumab: Transforming Immunotherapy and Skin Disease Management(Post)What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
Citrullination, NETs and Rheumatoid Arthritis(Page) Microglia and Neuroinflammation(Page) Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Anifrolumab: Transforming Lupus Treatment with Targeted Immunotherapy(Post)Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus eryth
Interferons(Post)Interferons (IFNs) are a group of signalling proteins that are produced and released from cells in response to viral infection and other stimuli such as normal and tumour cell survival and
CD Markers Expression on B Cells(Post)Immunology · ImmunophenotypingCD Markers on B Cells: Development, Subsets and ImmunophenotypingB cells change their surface marker profile at every stage from bone marrow progenitor to antibody-secret
CD73: Combating Tumor Immunosuppression by Targeting Adenosine(Post)Introduction to CD73 and Tumor Immunosuppression CD73, also known as ecto-5'-nucleotidase, is an enzyme found on the surface of various cells, including tumor cells and immune cells. It p
CD86: Enhancing T Cell Activation in Immunotherapy(Post)Introduction to CD86 and Its Role in Immune Activation CD86 is a crucial co-stimulatory molecule that plays an essential role in T cell activation, driving the immune system’s ability to
COVID-19 Biomarkers(Post)SARS-CoV-2 Background COVID-19 is characterised by a series of biological markers. In some instances, these biomarkers can be used as potenti
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity